153 related articles for article (PubMed ID: 24969114)
1. AACE/ACE Disease State Clinical Review: Dopamine Agonists for Hyperprolactinemia and the Risk of Cardiac Valve Disease.
Samson SL; Ezzat S
Endocr Pract; 2014 Jun; 20(6):608-16. PubMed ID: 24969114
[TBL] [Abstract][Full Text] [Related]
2. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.
De Vecchis R; Esposito C; Ariano C
Herz; 2013 Dec; 38(8):868-80. PubMed ID: 23743769
[TBL] [Abstract][Full Text] [Related]
3. A Follow-Up Study of the Prevalence of Valvular Heart Abnormalities in Hyperprolactinemic Patients Treated With Cabergoline.
Drake WM; Stiles CE; Bevan JS; Karavitaki N; Trainer PJ; Rees DA; Richardson TI; Baldeweg SE; Stojanovic N; Murray RD; Toogood AA; Martin NM; Vaidya B; Han TS; Steeds RP; ; Baldeweg FC; Sheikh UE; Kyriakakis N; Parasuraman SK; Taylor L; Butt N; Anyiam S
J Clin Endocrinol Metab; 2016 Nov; 101(11):4189-4194. PubMed ID: 27571182
[TBL] [Abstract][Full Text] [Related]
4. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.
Valassi E; Klibanski A; Biller BM
J Clin Endocrinol Metab; 2010 Mar; 95(3):1025-33. PubMed ID: 20130078
[TBL] [Abstract][Full Text] [Related]
5. [Cabergoline in hyperprolactinemia and valvular heart disease].
Vargas ML; Cervantes CE; Hernando CA; Da Costa CV
Endocrinol Nutr; 2009 Oct; 56(8):412-7. PubMed ID: 19959151
[TBL] [Abstract][Full Text] [Related]
6. Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study.
Budayr A; Tan TC; Lo JC; Zaroff JG; Tabada GH; Yang J; Go AS
BMC Endocr Disord; 2020 Feb; 20(1):25. PubMed ID: 32075620
[TBL] [Abstract][Full Text] [Related]
7. Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
Vallette S; Serri K; Serri O
Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):49-54. PubMed ID: 20014934
[TBL] [Abstract][Full Text] [Related]
8. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly.
Maione L; Garcia C; Bouchachi A; Kallel N; Maison P; Salenave S; Young J; Assayag P; Chanson P
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1714-9. PubMed ID: 22723314
[TBL] [Abstract][Full Text] [Related]
9. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.
Lafeber M; Stades AM; Valk GD; Cramer MJ; Teding van Berkhout F; Zelissen PM
Eur J Endocrinol; 2010 Apr; 162(4):667-75. PubMed ID: 20071478
[TBL] [Abstract][Full Text] [Related]
10. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.
Bogazzi F; Buralli S; Manetti L; Raffaelli V; Cigni T; Lombardi M; Boresi F; Taddei S; Salvetti A; Martino E
Int J Clin Pract; 2008 Dec; 62(12):1864-9. PubMed ID: 18462372
[TBL] [Abstract][Full Text] [Related]
11. A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists.
Drake WM; Stiles CE; Howlett TA; Toogood AA; Bevan JS; Steeds RP;
J Clin Endocrinol Metab; 2014 Jan; 99(1):90-6. PubMed ID: 24187407
[TBL] [Abstract][Full Text] [Related]
12. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
13. [Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].
Steffensen C; Mægbæk ML; Laurberg P; Andersen M; Kistorp C; Nørrelund H; Dal J; Jørgensen JO
Ugeskr Laeger; 2014 Jan; 176(1):58-60. PubMed ID: 24629610
[TBL] [Abstract][Full Text] [Related]
14. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies.
Bogazzi F; Manetti L; Raffaelli V; Lombardi M; Rossi G; Martino E
J Endocrinol Invest; 2008 Dec; 31(12):1119-23. PubMed ID: 19246980
[TBL] [Abstract][Full Text] [Related]
15. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
[TBL] [Abstract][Full Text] [Related]
16. Cardiopulmonary complications of ergot-derivative dopamine agonists.
Rack MJ; Baran AS; Richert AC; Roffwarg HP
J Clin Psychiatry; 2004 Oct; 65(10):1429-30; author reply 1430. PubMed ID: 15491249
[No Abstract] [Full Text] [Related]
17. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
Pullan PT
Intern Med J; 2009 Apr; 39(4):213-5. PubMed ID: 19402858
[No Abstract] [Full Text] [Related]
18. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia.
Devin JK; Lakhani VT; Byrd BF; Blevins LS
Endocr Pract; 2008 Sep; 14(6):672-7. PubMed ID: 18996784
[TBL] [Abstract][Full Text] [Related]
19. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
[TBL] [Abstract][Full Text] [Related]
20. Cabergoline and the risk of valvular lesions in endocrine disease.
Lancellotti P; Livadariu E; Markov M; Daly AF; Burlacu MC; Betea D; Pierard L; Beckers A
Eur J Endocrinol; 2008 Jul; 159(1):1-5. PubMed ID: 18456868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]